1. Scrip
  2. >>Business

Resilient US Rebif, Gonal-f Q2 Sales Allow German Merck To Up Forecast

 
• By Sten Stovall

Solid US demand for Gonal-f fertility and Rebif MS drugs in the second quarter – along with commissions from its Xalkori co-promotion partnership there with Pfizer – let Merck KGaA upgrade its guidance for the full year.

SC1608_UpgradeBlocks_1200x675

Germany's Merck KGAA – which is trying to transform itself into a top oncology and immuno-oncology innovator – lifted its full-year earnings forecast Aug 4 in part on the back of stable US sales for its Gonal-f fertility treatment after the recall of a rival product there, and for demand for its Rebif (interferon beta-1a) treatment for relapsing forms of multiple sclerosis, which faces competition from oral treatments.

The company said its priorities going forward are now boosting its pharma pipeline, further integration of chemicals and biologicals maker...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

 
• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

More from Scrip

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.